Back To The Day Job? AstraZeneca’s Pangalos Looks Ahead To A Post-Pandemic Pipeline
Vaccine Efforts Caused No Productivity Blip, Says R&D Head
Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.
You may also be interested in...
After an expensive and protracted construction, AstraZeneca hopes its Cambridge research center will help foster collaboration and extend its run of R&D success.
AstraZeneca’s creation of a new division does not mean it sees a long-term future for its COVID-19 vaccine.
In this week's podcast edition of Five Must-Know Things: AstraZeneca looks to return to normality; Bayer’s hopes for Kerendia; Novartis’s plans for a new version of Zolgensma; Arcturus benefits from mRNA interest; and AbbVie changes tack in Alzheimer’s.